GlobeImmune Adds To Series B

Louisville Colorado-based GlobeImmune announced this afternoon that it has added an additional $4.1M to the company's Series B funding round. The funding came from PAC-LINK Bio Venture Capital, China Investment and Development (CIDC) and Yasuda Enterprise Development. The additional investment brings its funding to a total of $38.4M raised in this round, including the first close. GlobeImmune said it will use the Series B for a Phase 2 clinical trial of its product targeted at pancreatic cancer. The Series B was led by Lilly Ventures. GlobeImmune is developing targeted molecular immunotherapy products. More information »